MG-132

Catalog No.S2619

MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

Price Stock Quantity  
USD 100 In stock
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MG-132 Chemical Structure

MG-132 Chemical Structure
Molecular Weight: 475.62

Validation & Quality Control

Product Use Citation(42)

Customer Product Validation(9)

Quality Control & MSDS

Related Compound Libraries

MG-132 is available in the following compound libraries:

Proteasome Inhibitors with Unique Features

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.
Targets Proteasome [1]
(Cell-free assay)
IC50 100 nM
In vitro MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LPS-stimulated RAW264.7 cellsM1noSmZ2dmO2aX;uJGF{e2G7NGj3WGMzPSEQvF2=MWfEUXNQM2\zfGlvcGmkaYTzJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAxNjFizszNNYH6S3NUOjR4OUe0PVY>
HL-60NUe3SlV[S3m2b4TvfIlkKEG|c3H5MXO0NEDPxE1?Mk\rOFghcA>?M2LWPWROW09?NH;iW5lKSzVyPEGwJO69VQ>?MUCyOFY6PzR7Nh?=
SMMC-7721NX\mXGpPS3m2b4TvfIlkKEG|c3H5NVHUeIZzPDBizszNNGTacoI1QCCqMlfXSG1UVw>?MkiwTWM2OD15LkGg{txONETSNFUzPDZ7N{S5Oi=>
A-549Ml\wR5l1d3SxeHnjJGF{e2G7NGH5Z2Q1OCEQvF2=Mn;ZOFghcA>?MoLSSG1UVw>?MXTJR|UxRDFyIN88US=>Mnr3NlQ3QTd2OU[=
MCF-7M4DrR2N6fG:2b4jpZ{BCe3OjeR?=MorZOFAh|ryPMkHHOFghcA>?NFHFeXNFVVORNEe3OXBKSzVyPUeuN{DPxE1?M4C0dlI1Pjl5NEm2
SW-480NWDxUHhiS3m2b4TvfIlkKEG|c3H5MofROFAh|ryPNH7QbHI1QCCqMofuSG1UVw>?NYTJOXhPUUN3ME20JO69VQ>?NWfWVXhvOjR4OUe0PVY>
NCI-H929MYXDfZRwfG:6aXOgRZN{[Xl?MVuxJO69VQ>?MUG3NkBpMWLEUXNQM2H0e2lEPTB;MD6xO{DPxE1?MmTVNlQ3OjVyOEi=
293TM2C4dGN6fG:2b4jpZ{BCe3OjeR?=M4nqTVExKM7:TR?=NFiz[JQ4OiCqMYLEUXNQNWf5bnRqUUN3MEyyJO69VQ>?NUHqT5FsOjR4MkWwPFg>
293TM2fZXmZ2dmO2aX;uJGF{e2G7NYjmPYltOTBizszNMl3zNlQhcA>?NWrJO4o{TE2VTx?=M2rW[W1w\GW{YYTlcJkhcW6mdXPld{Bp\WG2LYPoc4NsKCB?NGPmVmczPDZ{NUC4PC=>
HeLaNEXPVFlMcW6jc3WgRZN{[Xl?MkLvNVAh|ryPNF;RTY0yKGh?MnfzSG1UVw>?Mn61TY5lfWOnczDQRXJRKGOuZXH2ZYdmKGK7IHnubIljcXSrbnegdJJwe2Wjc3;t[UBi[3Srdnn0fS=>MoT0NlQ{OjF6M{O=
MDA-MB-231NWjHbXNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3flSFEh|ryPNEfxcJc4OiCqNUDyd5A6TE2VTx?=M1;hcWlEPTB;MD6xPEDPxE1?MUmyOFE2OzJyNh?=
MCF-7MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTxZ|M6OSEQvF2=MkHoO|IhcA>?M4DyPGROW09?MmLxTWM2OD1yLkGzJO69VQ>?NVfsTmVQOjRzNUOyNFY>
MCF10ANFzQNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\r[FEh|ryPMVK3NkBpMULEUXNQM4LZSGlEPTB;MD6yPUDPxE1?Mn;rNlQyPTN{ME[=
HEK-293NHrhRVdMcW6jc3WgRZN{[Xl?M1\hOVIh[W6mIEKwJO69VQ>?M1\TUlIhcA>?M1Ky[mROW09?M2LucWlvcGmkaYTzJGNpXC2OIHHjeIl3cXS7IIfpeIghUUN3MDDv[kA6KG6PIB?=NGH1UHAzOzV2MEe5NC=>
Calu6Mlf1SpVv[3Srb36gRZN{[Xl?MVixNEDPxE1?MmDwNVghcA>?MVLEUXNQNGrhTlBUcWewaX\pZ4FvfGy7IHHjZ5VufWyjdHXzJIZz[XSjeHnuJJBz\WO3coPvdi=>Mo[1NlM2ODZ2OE[=
IFN-gamma-induced RAW264.7NGT2SlFHfW6ldHnvckBCe3OjeR?=M1Gx[2ROW09?MVzJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4xPzdizszNMYqyNlI4PzJ5Nx?=
IPC227FM2e4VGN6fG:2b4jpZ{BCe3OjeR?=MkLhNUDPxE1?NVfMd|JuPDhiaB?=MmLQSG1UVw>?NFzEfpJKSzVyPUCuNFc4KM7:TR?=NEPDcWIzOTl{NEWyPC=>
Hepa-1c1c7MlXqSpVv[3Srb36gRZN{[Xl?NFrM[mMzPSEQvF2=MUm2JIg>NYTPZnNpTE2VTx?=NVnxdZNyUW6lcnXhd4V{KE6{ZkKgdJJwfGWrbjDs[ZZmdA>?NUPNSFlVOjB|OUK1OFQ>
COS-7NIXiZ2JEgXSxdH;4bYMhSXO|YYm=MlTINVAh|ryPNXf1NVhOTE2VTx?=NETXcoRKSzVyPEGwJO69VQ>?MYSxPFA5QDB7Nx?=
HuH-7NEDvUGhEgXSxdH;4bYMhSXO|YYm=M{njT|ExKM7:TR?=NWPOboY{TE2VTx?=NInURYFKSzVyPEGwJO69VQ>?NYOycVdsOThyOEiwPVc>
OCI-Ly3NVLmbo9GTnWwY4Tpc44hSXO|YYm=NFLBT4oyOCEQvF5CpC=>MVm0JIg>MYLEUXNQNHTXbWhKdmS3Y3XzJIh2dWGwIFnrZZBx[UKjbIDoZUB{fGGkaXzpfoF1cW:wIIfpeIghTUN3MDDv[kAyKM7:TR?=MkjNNVgxOjRzMUO=
A2780 cDDPM1PFWmFxd3C2b4Ppd{BCe3OjeR?=NF3PeVgzPCCqMWDEUXNQNUHWR5AzUW6mdXPld{BieG:ydH;zbZMh[nliaX7obYJqfGmwZzDQWGVPKGSnZ4Lh[IF1cW:wM3;YVFE4Pjh2MEG4
LPS-stimulated RAW264.7 cellsNV[1WnV4TnWwY4Tpc44hSXO|YYm=M1TmdmROW09?M2e2U2lvcGmkaYTzJG5HNWujcIDhRkBFVkFiYnnu[Ilv\w>?NXXS[mpzOTd2MEeyO|c>
PC12M1\BPWZ2dmO2aX;uJGF{e2G7Mn3zNVAxKM7:TdMgNGDqc2ozPCCqMYDEUXNQMYPJcohq[mm2czC2MW9JTEFvIHHu[EBJOk9{LXnu[JVk\WRiY4n0c5RwgGmlaYT5NEXNNooyPzF3OES1OC=>
PC3MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXWNlAh|ryPNVrJPVN4PDhiaB?=MXTEUXNQMmf3TWM2OD1yLk[g{txOM33sSFE3Pjh4NUO3
LP-1NEnYUpRCeG:ydH;zbZMhSXO|YYm=NYLPdVdKOzByIH7NM1jjSlI1KGh?NVLsS3I{TE2VTx?=Mn:yTY5lfWOnczDhdI9xfG:|aYOgZpkhcW6lcnXhd4lv\yClbHXheoVlKFCDUmCgcIV3\WxiYX7kJJJm\HWlaX7nJG1kdC1zIIDyc5RmcW5ibHX2[Yw>M{\SO|E2QTV6NUi5
ES6M4LOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVX0PWhJUUN3ME2wMlAyOzB4IN88US=>NGjwOpVUSU6JRWK=
A101DM4TpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFT0VHJKSzVyPUCuNFMzPzlizszNMXHTRW5ITVJ?
OCUB-MNV3WeWd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVKwfopCUUN3ME2wMlA{PzN5IN88US=>NInP[mlUSU6JRWK=
LB2518-MELM4DJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHlepJCUUN3ME2wMlA{PzZizszNNFfhOpFUSU6JRWK=
SH-4M4rCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHWOmxNUUN3ME2wMlA1OzFizszNNIPrblhUSU6JRWK=
KNS-42MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTBwMES0OFEh|ryPM3rtWnNCVkeHUh?=
DSH1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3OPYNKSzVyPUCuNFUzQDlizszNM{HEdnNCVkeHUh?=
NTERA-S-cl-D1NYPnTJpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;iSVdKSzVyPUCuNFU4PzJizszNNU\lfZFsW0GQR1XS
D-542MGNWm0UJYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrnSYFKSzVyPUCuNFU6PTdizszNMknwV2FPT0WU
KS-1NESyWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LiTWlEPTB;MD6wOlQ2QCEQvF2=NYryVGdRW0GQR1XS
BL-41M3rhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTBwME[5OFch|ryPNXHjWoV{W0GQR1XS
LXF-289NVHCdppKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3oZYJWUUN3ME2wMlA4ODZ4IN88US=>NVjmPINMW0GQR1XS
D-247MGNF3xTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDkTWM2OD1yLkC3NlA6KM7:TR?=M2T1RnNCVkeHUh?=
MMAC-SFM4jVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLmTWM2OD1yLkC3NlY5KM7:TR?=NX\Yb25UW0GQR1XS
CP66-MELNF;oWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2D2U2lEPTB;MD6wO|Uh|ryPMX3TRW5ITVJ?
LB771-HNCMl\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTlTWM2OD1yLkC4NFM3KM7:TR?=NIHqd2hUSU6JRWK=
no-10M13tSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXOTWM2OD1yLkC4PVA6KM7:TR?=M1O4[nNCVkeHUh?=
A388M1vCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3OdXhuUUN3ME2wMlA6ODZ3IN88US=>M2\N[XNCVkeHUh?=
OPM-2NXu0Nm9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXr2[ZgzUUN3ME2wMlExPDd2IN88US=>Ml;0V2FPT0WU
OVCAR-4MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTBwMUC5N|gh|ryPMYjTRW5ITVJ?
HOP-62MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDGXItKSzVyPUCuNVA6PDlizszNNG\RUJdUSU6JRWK=
ML-2MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvGb2g2UUN3ME2wMlEyQDB4IN88US=>MWrTRW5ITVJ?
UACC-257NGTwdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXZU3FKSzVyPUCuNVE6OjdizszNMWnTRW5ITVJ?
NEC8MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHKzWmhKSzVyPUCuNVE6QTVizszNMkXuV2FPT0WU
ONS-76NXXjXHhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\Ob3JnUUN3ME2wMlEzQTN3IN88US=>MmLGV2FPT0WU
KE-37NWDrdJdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXFO21KSzVyPUCuNVMzPzhizszNM{fZN3NCVkeHUh?=
HT-144NF\1W2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{W2eGlEPTB;MD6xN|g6PSEQvF2=NFy5[lhUSU6JRWK=
LB2241-RCCMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkP0TWM2OD1yLkG0NlQ4KM7:TR?=MVzTRW5ITVJ?
TE-5M2HBemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEeyS5FKSzVyPUCuNVQzPzhizszNNILmSppUSU6JRWK=
KINGS-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\4TWM2OD1yLkG0O|kh|ryPM{DWeHNCVkeHUh?=
NCI-H69MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnUR4FuUUN3ME2wMlE2OTRzIN88US=>MUHTRW5ITVJ?
CAS-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrlenJKSzVyPUCuNVU1QDJizszNMXjTRW5ITVJ?
D-263MGMnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTBwMU[wNFYh|ryPNY\COY1QW0GQR1XS
A253NYjHeYtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3FfIRKSzVyPUCuNVYyOjhizszNNULLS5dkW0GQR1XS
PF-382NHzDV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rpOWlEPTB;MD6xOlcxPiEQvF2=MkjNV2FPT0WU
CESSM13Ldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPHTWM2OD1yLkG3NFYh|ryPMoG5V2FPT0WU
MZ2-MELMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DXbmlEPTB;MD6xO|U2QSEQvF2=MofxV2FPT0WU
HELNHrU[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2T3NWlEPTB;MD6xPFUyPyEQvF2=M1faPXNCVkeHUh?=
D-392MGNXfQUWlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\TXJdKSzVyPUCuNVkyOTVizszNMVvTRW5ITVJ?
SK-LMS-1NF[2emJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfJXpk1UUN3ME2wMlE6OzB|IN88US=>MV3TRW5ITVJ?
GI-ME-NMnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVfBZ|FwUUN3ME2wMlE6OzB4IN88US=>MmG5V2FPT0WU
LB831-BLCNFrZN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vBbWlEPTB;MD6xPVM1KM7:TR?=NWnVbIdCW0GQR1XS
DU-4475NWThbFk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjsTWM2OD1yLkG5OlU5KM7:TR?=M2T3SXNCVkeHUh?=
IST-SL1MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fXbWlEPTB;MD6yNFA6PCEQvF2=NU\kZVFxW0GQR1XS
GAKMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTBwMkC1N|Qh|ryPMnywV2FPT0WU
EW-1NHvsW|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfKU|FVUUN3ME2wMlIyODR5IN88US=>M2LXb3NCVkeHUh?=
LAMA-84NGDIR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7STWM2OD1yLkKxPFUyKM7:TR?=NGLoTVdUSU6JRWK=
SK-UT-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1y1SGlEPTB;MD6yNlA1QSEQvF2=NYnNfVVHW0GQR1XS
VA-ES-BJNWT1PHZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17EUWlEPTB;MD6yNlI2PyEQvF2=MnTmV2FPT0WU
ACNNFTaPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XCVmlEPTB;MD6yNlY{QCEQvF2=MYnTRW5ITVJ?
SK-PN-DWNFrtZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fMN2lEPTB;MD6yN|E6KM7:TR?=NYrmTIZlW0GQR1XS
HD-MY-ZNX\RcngzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlO0TWM2OD1yLkKzN|A{KM7:TR?=MXjTRW5ITVJ?
LB373-MEL-DNV;0VpFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTBwMkSxPVgh|ryPMXTTRW5ITVJ?
COLO-829Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTBwMkSyOVch|ryPNUXSe2J5W0GQR1XS
ES8NUHHb3BFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHvTWM2OD1yLkK0O|Y{KM7:TR?=M3TldHNCVkeHUh?=
RXF393NEDhNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HPXWlEPTB;MD6yOVAyPSEQvF2=MXPTRW5ITVJ?
TK10NEjteWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7jW5ZKSzVyPUCuNlU1OzVizszNM{f0ZXNCVkeHUh?=
LOUCYM{PzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTBwMkW0OVYh|ryPMlnvV2FPT0WU
MZ7-melMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWr5dWRJUUN3ME2wMlI3Ozd2IN88US=>MoDHV2FPT0WU
CP67-MELNFTqVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7oTWM2OD1yLkK2O|Mh|ryPMnz2V2FPT0WU
C2BBe1NV\PZnhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLEN211UUN3ME2wMlI4QTB5IN88US=>M{O5b3NCVkeHUh?=
K052MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTBwMki5PUDPxE1?MlK2V2FPT0WU
MOLT-16NWqzfIxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTBwMkm1NlQh|ryPMnfmV2FPT0WU
KNS-81-FDMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDSfIdKSzVyPUCuN|A{OjNizszNMk\sV2FPT0WU
CMKM3:0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljHTWM2OD1yLkOxNVIh|ryPNUfDTnViW0GQR1XS
LAN-6MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HycGlEPTB;MD6zNVMh|ryPMnjXV2FPT0WU
KLENGe0XY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLSTWM2OD1yLkOxN|A3KM7:TR?=NIHhOGVUSU6JRWK=
NCCITNIe0PI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTBwM{G3PFMh|ryPNFm5XG9USU6JRWK=
HHNX[wOHV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHWNZhKSzVyPUCuN|I5QTdizszNMY\TRW5ITVJ?
TE-8MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXCOIpvUUN3ME2wMlM1Ojd7IN88US=>MWXTRW5ITVJ?
GDM-1Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3SyT2lEPTB;MD6zOVExPCEQvF2=NFrjRmxUSU6JRWK=
NCI-H747MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTBwM{exNFMh|ryPNYiyfFR5W0GQR1XS
NCI-H1092MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGi1bnNKSzVyPUCuN|g5PDRizszNNYrTdoFjW0GQR1XS
8-MG-BANYKzfGdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfVOVJKSzVyPUCuN|k5OzdizszNMUjTRW5ITVJ?
NB17M1LCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTBwNEK5O{DPxE1?NEjs[JdUSU6JRWK=
LC4-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmrBTWM2OD1yLkSzOlA4KM7:TR?=NGDjXJNUSU6JRWK=
TE-1NF64dpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTBwNEWxNVkh|ryPM4PkNHNCVkeHUh?=
KALS-1M{Txfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjtNlNKSzVyPUCuOFY2QDRizszNNIHGc25USU6JRWK=
CCRF-CEMM3m1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTBwNEe2O|Qh|ryPNHj4V3BUSU6JRWK=
OS-RC-2NF3OepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTBwNEe5O|Ih|ryPNEL4ZoxUSU6JRWK=
A704NGW4cXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnsPJdKSzVyPUCuOFg3QTJizszNM{H5c3NCVkeHUh?=
BB49-HNCMnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDmZ3NKSzVyPUCuOFkxQTZizszNM3nGV3NCVkeHUh?=
EVSA-TNGDWNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;YTZNKSzVyPUCuOFk6OTFizszNM2HhOnNCVkeHUh?=
Mo-TMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfTTWM2OD1yLkWxO|YzKM7:TR?=MonaV2FPT0WU
MONO-MAC-6MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\oR2xKSzVyPUCuOVM3OTFizszNMYHTRW5ITVJ?
BB65-RCCM2Pjdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1y0TmlEPTB;MD61OlgyOSEQvF2=M13ucHNCVkeHUh?=
NCI-H1882M2\aTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLQOYRKSzVyPUCuOVkxOzZizszNMlTMV2FPT0WU
TE-9NXPKfYx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NED4d|dKSzVyPUCuOlExOzNizszNNWm2dWdUW0GQR1XS
NCI-H2126NG\5PHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLMTWM2OD1yLk[yOlY6KM7:TR?=NFi2UnpUSU6JRWK=
SF268NV;GUIxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjmTWM2OD1yLk[1OlQyKM7:TR?=MX\TRW5ITVJ?
SW872M2ryWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LxSmlEPTB;MD62OVczQSEQvF2=NY\xeIJVW0GQR1XS
LS-513M33BOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHFbllwUUN3ME2wMlY3PzVzIN88US=>NEPxbopUSU6JRWK=
NCI-H1355M{T4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrmb21GUUN3ME2wMlY5PjF7IN88US=>M17ycnNCVkeHUh?=
BL-70M1nU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTBwNkmzPFgh|ryPMVnTRW5ITVJ?
NCI-SNU-5Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLiTWM2OD1yLk[5OVQ2KM7:TR?=M4PEW3NCVkeHUh?=
SNU-C2BMmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TxSGlEPTB;MD63NFc{QSEQvF2=MWHTRW5ITVJ?
GB-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3xdlhKSzVyPUCuO|IyOjRizszNNYXuNIpLW0GQR1XS
CTB-1M12xfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjFTWM2OD1yLke3PVU2KM7:TR?=MWjTRW5ITVJ?
BeckerMoj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XwTmlEPTB;MD63PVYzOSEQvF2=MUTTRW5ITVJ?
KM12MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfhT|FKSzVyPUCuPFU1PjZizszNM2Dt[XNCVkeHUh?=
ES7M2Pzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTBwOEm2OUDPxE1?M4PQZ3NCVkeHUh?=
COLO-684NInQTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnETFVKSzVyPUCuPVA3PThizszNMlPHV2FPT0WU
HCC2998NF3HcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV72V5dEUUN3ME2wMlk{QDV2IN88US=>NXXw[WxxW0GQR1XS
TE-10MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnuTWM2OD1yLkm2OFMh|ryPM4PPZ3NCVkeHUh?=
SF126MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDYblhKUUN3ME2wMlk5QTdzIN88US=>NVri[WJ6W0GQR1XS
EKVXMnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDDd|VKSzVyPUGuNFM1PDJizszNMn3tV2FPT0WU
KARPAS-45NIThPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4[0bWlEPTB;MT6wOFAyPiEQvF2=MYHTRW5ITVJ?
KGNM4HSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTtN4FnUUN3ME2xMlA2ODR3IN88US=>NWHEdWRWW0GQR1XS
ES1Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHKToJKSzVyPUGuNFc6OjFizszNNVHVcYFSW0GQR1XS
L-540NWLrcnlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPTTWM2OD1zLkGxPFM6KM7:TR?=NXfofolrW0GQR1XS
KURAMOCHIM4rFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVixcmxyUUN3ME2xMlEzOzd2IN88US=>MlzVV2FPT0WU
LU-65MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkKwTWM2OD1zLkGyO|U{KM7:TR?=MmfiV2FPT0WU
MFH-inoM3vDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonJTWM2OD1zLkG3OVAyKM7:TR?=MmjwV2FPT0WU
NCI-H23MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHITodmUUN3ME2xMlIxPDFizszNNGLkT|NUSU6JRWK=
IA-LMM370dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\5XnhKSzVyPUGuNlQyOTZizszNMlHxV2FPT0WU
PSN1Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIm0V2dKSzVyPUGuNlcxOTZizszNMlz2V2FPT0WU
NCI-H719M37LO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\QTWM2OD1zLkK3OFEyKM7:TR?=MXLTRW5ITVJ?
SW684MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTFwMki2OVkh|ryPMoi4V2FPT0WU
HCE-4Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrx[ZhzUUN3ME2xMlMxOjJzIN88US=>NHnPWVNUSU6JRWK=
EW-16MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3W5eGlEPTB;MT6zNVM1PyEQvF2=NGnU[IZUSU6JRWK=
NCI-H128NHLaR2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTFwM{W4NVQh|ryPNFHRdGtUSU6JRWK=
HC-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7YfmczUUN3ME2xMlM5OTdizszNNFrrZnFUSU6JRWK=
IST-MES1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\ucGlEPTB;MT60NFIxQCEQvF2=MkPGV2FPT0WU
RajiMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2Hl[mlEPTB;MT60NVg2KM7:TR?=M4LiUXNCVkeHUh?=
DMS-114NHXCSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofFTWM2OD1zLkS0OVM6KM7:TR?=MXXTRW5ITVJ?
GI-1MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTFwNEexN|Eh|ryPNGTLUmZUSU6JRWK=
NCI-H2081M{fKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTFwNUWxPVYh|ryPM4Sx[HNCVkeHUh?=
LC-1FM1\iOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPlPIU6UUN3ME2xMlU2OTl6IN88US=>M1TpU3NCVkeHUh?=
NCI-H2227MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofQTWM2OD1zLk[xOVYyKM7:TR?=M1PhenNCVkeHUh?=
D-502MGMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PJSGlEPTB;MT62O|IyOSEQvF2=NFTFTHJUSU6JRWK=
NCI-H2141M3;rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTFwNkezNVch|ryPNHXlZY9USU6JRWK=
LS-411NMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTWcopKSzVyPUGuOlk5ODdizszNM{P3cHNCVkeHUh?=
SU-DHL-1MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoeyTWM2OD1zLkexNlgyKM7:TR?=NYi1WllqW0GQR1XS
BB30-HNCNWHMfYU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF:5VFhKSzVyPUGuO|I3QDVizszNM4Dxb3NCVkeHUh?=
TE-15MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLlXGZIUUN3ME2xMlkzOzd|IN88US=>M2qwT3NCVkeHUh?=
JVM-3NXyxPYZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTFwOUO5NFQh|ryPM37sfHNCVkeHUh?=
IST-SL2M{jHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTJwMEGyOVIh|ryPNWrldW5[W0GQR1XS
EW-18NHjkWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\nTWM2OD1{LkCyN|M4KM7:TR?=MmewV2FPT0WU
DJM-1NEn6OpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfyTWM2OD1{LkCyOVUzKM7:TR?=NFzhbolUSU6JRWK=
no-11NIfEbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzySohiUUN3ME2yMlA{OTB2IN88US=>MkLmV2FPT0WU
QIMR-WILNGnkRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTJwMU[3OlIh|ryPM3SxbnNCVkeHUh?=
MC-CARNHrxO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTJwMkK5OUDPxE1?Mm\XV2FPT0WU
KM-H2M3;QPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjRXIJKSzVyPUKuNlkxPDNizszNMl7nV2FPT0WU
ECC12NUD0WWlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnH4TWM2OD1{LkO3PVQh|ryPMnLkV2FPT0WU
HCE-TMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTJwNES4PFMh|ryPM3;I[3NCVkeHUh?=
MFM-223NGSxSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPXeG9KSzVyPUKuOVA5PzFizszNNVLUcXpmW0GQR1XS
SW982MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\QOVVKSzVyPUKuOVE1QCEQvF2=NFLPV2VUSU6JRWK=
KG-1NFjCeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTLOJc6UUN3ME2yMlg5PzlzIN88US=>NWnWUGVbW0GQR1XS
ES4MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTNwME[xNVEh|ryPNIPGS25USU6JRWK=
SCC-3NUHGcndMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrSSlVKSzVyPUOuNVA5PDhizszNMlTwV2FPT0WU
RH-1NI\pepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXH4UFZxUUN3ME2zMlM5PzR6IN88US=>M4\lXHNCVkeHUh?=
NCI-H748MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTNwNESyOlYh|ryPMYPTRW5ITVJ?
HCC2218NGfBeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\GeY1KSzVyPUOuOFY6OzdizszNM2PHeXNCVkeHUh?=
MEG-01MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnqxTWM2OD1|LkW5Olgh|ryPNFXneHVUSU6JRWK=
NB12NVy5OY9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTNwNUm4PFgh|ryPMnr2V2FPT0WU
SNB75MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjpTIVJUUN3ME2zMlYxOTB|IN88US=>MkK3V2FPT0WU
KMS-12-PEM3Ozbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnO2TWM2OD1|Lk[3O|I{KM7:TR?=MlXZV2FPT0WU
SKM-1NWLuTIQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTNwN{GzO|Yh|ryPNWDKTo5iW0GQR1XS
COLO-320-HSRM13JVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjhZW5KSzVyPUOuO|U3OzRizszNNIj2bG5USU6JRWK=
NKM-1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjTU2tKSzVyPUOuO|c{PzhizszNNVraWJJnW0GQR1XS
TE-6NVnTTlJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXraV5pGUUN3ME2zMlk1PTZzIN88US=>M{Lh[3NCVkeHUh?=
D-336MGNVr5Rmd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTRwMEGxOlYh|ryPM1L6[XNCVkeHUh?=
NCI-H1650NI\iSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHzTYJVUUN3ME20MlE2Pzl5IN88US=>NFrWV3pUSU6JRWK=
ES3MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHZNZRtUUN3ME20MlMzQDJ2IN88US=>MVjTRW5ITVJ?
YTMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzUTWM2OD12LkO1OFI1KM7:TR?=MYnTRW5ITVJ?
ES5MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfFb4ZHUUN3ME20MlQxOjV3IN88US=>NFHtOGlUSU6JRWK=
LB647-SCLCNWfS[2hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPZdVhCUUN3ME20MlU3OzB6IN88US=>NEnKcGRUSU6JRWK=
HAL-01NFLB[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEK5dWVKSzVyPUSuOVcxOzRizszNMmLnV2FPT0WU
LP-1NXXWUXRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVX3PYFMUUN3ME20MlczOzdzIN88US=>MXLTRW5ITVJ?
BC-1M{nhSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jsWWlEPTB;NT6wNFQ1PyEQvF2=NVrBTXVyW0GQR1XS
EB-3M3WyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVztVo1VUUN3ME21MlA{ODRzIN88US=>NVLieVRPW0GQR1XS
GT3TKBNE\4d3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfLbHhEUUN3ME21MlE4PjZ{IN88US=>MkXEV2FPT0WU
NCI-H209MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkHqTWM2OD13LkG5N|UzKM7:TR?=NIHaT5lUSU6JRWK=
BT-474NWLxPYR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1P0eGlEPTB;NT6yN|ExOiEQvF2=NFjLT5VUSU6JRWK=
RKONEGwcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\6RXFKSzVyPUWuNlM1OjJizszNMVXTRW5ITVJ?
SIMAMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3q1Z2lEPTB;NT6zNFc3PSEQvF2=NEfnR2hUSU6JRWK=
RLMmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTVwM{e1OFEh|ryPMnrZV2FPT0WU
GCIYMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4q3fGlEPTB;NT60O|I{PiEQvF2=NHK4XoJUSU6JRWK=
Calu-6NY\PW3BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHhOpVKSzVyPUWuOlIzKM7:TR?=M2LHO3NCVkeHUh?=
ALL-POMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTVwNkO3PVUh|ryPNHvOZXRUSU6JRWK=
ARH-77M3\SR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTVwNkewPFch|ryPNUmzToxuW0GQR1XS
A4-FukNV\pSGt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17abmlEPTB;Nj6wPFEyQCEQvF2=NYTnNlhCW0GQR1XS
NCI-H1581NF7WcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGC2XYFKSzVyPU[uNlM5PDlizszNNXuxOHBXW0GQR1XS
HUTU-80MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3ob4NKSzVyPU[uN|Y5QTdizszNMV7TRW5ITVJ?
TGWNYD5W4JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3aeYNKSzVyPU[uOFU2QTNizszNNH3B[YVUSU6JRWK=
SK-N-FIMl7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTZwNEW4OVQh|ryPMoW0V2FPT0WU
U-266NFfjdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHjTWM2OD14LkWxPVI3KM7:TR?=Mn[4V2FPT0WU
EM-2NGe1VWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jVOGlEPTB;Nj62O|A6QSEQvF2=M2DJSnNCVkeHUh?=
NMC-G1M33XNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvjdHMzUUN3ME22MlcyQDl3IN88US=>M2TYWnNCVkeHUh?=
KASUMI-1NVPwWmxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW[xdGRSUUN3ME22Mlg1Pzh5IN88US=>MlfoV2FPT0WU
NALM-6NFz5bJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13GWWlEPTB;Nj64Olc2PCEQvF2=MX7TRW5ITVJ?
OCI-AML2MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLiTWM2OD15LkCwN|I3KM7:TR?=MnrBV2FPT0WU
SHP-77MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTdwMkK0N{DPxE1?NYiwWo1yW0GQR1XS
NOMO-1NVSxN2tFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHDWY0zUUN3ME23MlI1OjV2IN88US=>MkLaV2FPT0WU
SK-N-DZNXG5V3d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYD1TXV[UUN3ME23MlcyODh7IN88US=>MXXTRW5ITVJ?
LB1047-RCCNH\UdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTdwN{KyN|Eh|ryPMVrTRW5ITVJ?
MZ1-PCM3rNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXITWM2OD15Lki2OVU5KM7:TR?=MlnyV2FPT0WU
NB10M1zkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPnfllKSzVyPUeuPVk2PTZizszNM1nyZXNCVkeHUh?=
RL95-2MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDhZZhKSzVyPUiuNVA5PDJizszNM{L4VHNCVkeHUh?=
OMC-1M3zRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnIOmVSUUN3ME24MlUzOTlzIN88US=>MnPRV2FPT0WU
D-283MEDMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3hb5dKSzVyPUiuPVE4OTlizszNNXTLWnFyW0GQR1XS
MC116MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGj2SnRKSzVyPUiuPVc6PCEQvF2=MoPGV2FPT0WU
SJSA-1NXjFPG1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnHOmU3UUN3ME25MlA6ODlzIN88US=>MVPTRW5ITVJ?
JiyoyeP-2003MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjONFhKSzVyPUmuNlk{OTdizszNM37mTXNCVkeHUh?=
IST-MEL1NHyy[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HUZmlEPTB;OT63OFE6QCEQvF2=M4PFcXNCVkeHUh?=
CTV-1NUHLXllpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;3NmlEPTB;MUCuNFk4QSEQvF2=MnLoV2FPT0WU
NH-12NFfYTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\OXXdKSzVyPUGwMlI1OzNizszNMnzlV2FPT0WU
CA46Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nkSWlEPTB;MUCuN|YyKM7:TR?=M1XRPHNCVkeHUh?=
NCI-SNU-1NGDWbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmP2TWM2OD1zMD60PVY6KM7:TR?=NF;YVmxUSU6JRWK=
SCLC-21HMnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkO0TWM2OD1zMD62OVk3KM7:TR?=Ml;tV2FPT0WU
EC-GI-10M{G2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzaTWM2OD1zMD63NFMyKM7:TR?=NYTJfVJzW0GQR1XS
SRNYO1eGpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIX4Sm5KSzVyPUGxMlAyQDVizszNM4\GPHNCVkeHUh?=
NCI-H1648MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTFzLkC5OlUh|ryPMVHTRW5ITVJ?
TGBC1TKBNWjxV486T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTFzLkSxNFIh|ryPMUnTRW5ITVJ?
EW-11MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPYVJBNUUN3ME2xNU42OTh4IN88US=>NWHSUmxHW0GQR1XS
SK-MM-2MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPZTWM2OD1zMT64NFYyKM7:TR?=M{fzbXNCVkeHUh?=
NCI-H524MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITNVVVKSzVyPUGxMlk5OjJizszNMnHmV2FPT0WU
NOS-1MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrq[nlJUUN3ME2xNk4xOzR3IN88US=>M2fpd3NCVkeHUh?=
AM-38NVfGclV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVf6TFJNUUN3ME2xNk42PjN|IN88US=>Mnj5V2FPT0WU
A498MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHNTWM2OD1zMj63NFY6KM7:TR?=NX;KOFRqW0GQR1XS
KARPAS-422MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULlV|l[UUN3ME2xNk44PDl4IN88US=>MkHNV2FPT0WU
LU-139MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33Z[2lEPTB;MUKuPVAzPiEQvF2=M1riXnNCVkeHUh?=
COR-L88NYHHWnZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\RVWlEPTB;MUKuPVM5OiEQvF2=M{H2V3NCVkeHUh?=
K5MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnLGTWM2OD1zMj65OFYzKM7:TR?=M4TmPXNCVkeHUh?=
NB13NYjDR41oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rz[2lEPTB;MUKuPVc5OyEQvF2=NVy2OWx2W0GQR1XS
MRK-nu-1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLCRYtFUUN3ME2xN{4yQTVizszNMVHTRW5ITVJ?
MHH-NB-11NVLvUZdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTF|LkK5NFIh|ryPNVLQSogzW0GQR1XS
KU812NYDnT5JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo[0TWM2OD1zMz62NVI1KM7:TR?=MV7TRW5ITVJ?
TE-12NXnqdZQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnKTWM2OD1zMz62PVk1KM7:TR?=MULTRW5ITVJ?
NCI-N87NFu2PIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\zO2lEPTB;MUOuO|M3KM7:TR?=MlS0V2FPT0WU
EB2MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fSfWlEPTB;MUOuPFUxPSEQvF2=NELLPXZUSU6JRWK=
DBMnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTF|Lkm4PFUh|ryPM2fYXnNCVkeHUh?=
697MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn31TWM2OD1zND60OVEyKM7:TR?=MljmV2FPT0WU
MSTO-211HMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzKclZKSzVyPUG0Mlc1PDhizszNMkj2V2FPT0WU
JVM-2NYXyS5VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4TYUmlEPTB;MUSuO|c{PSEQvF2=MlPQV2FPT0WU
COLO-824NIf6NXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLhTWM2OD1zND63PVk1KM7:TR?=M{XZT3NCVkeHUh?=
BC-3NWL4bWtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofCTWM2OD1zNT6zPVgh|ryPM{nUNXNCVkeHUh?=
BOKUMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3SdGxKSzVyPUG1Mlk3ODhizszNMVPTRW5ITVJ?
GOTONW\hOmlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTF4Lkm2NVch|ryPMlTzV2FPT0WU
HCC2157MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDUTWM2OD1zNz60O|U2KM7:TR?=MVzTRW5ITVJ?
LS-1034MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnaWpJKSzVyPUG3MlY5OThizszNMnGxV2FPT0WU
CAL-148MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPOT29KSzVyPUG3Mlk4QTZizszNNF\R[I1USU6JRWK=
MOLT-4NE\oeJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7UTWM2OD1zOD64NlA5KM7:TR?=MmTJV2FPT0WU
DaudiMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7tTWM2OD1zOD65NlMyKM7:TR?=NYG4PZVbW0GQR1XS
J-RT3-T3-5MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XGTGlEPTB;MUmuOFA3PiEQvF2=NHyzTm9USU6JRWK=
KMOE-2NYfHXoxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTF7Lk[0PFIh|ryPNXK1SoREW0GQR1XS
HL-60MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYD5fWtCUUN3ME2yNE4yQTZ3IN88US=>MojiV2FPT0WU
P31-FUJMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDwXGRKSzVyPUKwMlQ4PTNizszNNGfqfotUSU6JRWK=
IM-9MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTJyLk[yNlQh|ryPNWDrVWNPW0GQR1XS
HDLM-2M1mzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37NO2lEPTB;MkCuPFgzOSEQvF2=NX7RUYVpW0GQR1XS
NCI-H1304M13KS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPCTWM2OD1{MT6wN|EyKM7:TR?=MXXTRW5ITVJ?
NCI-H345NX7FWVAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmCwTWM2OD1{MT6wOlQ{KM7:TR?=Mo[xV2FPT0WU
RPMI-6666MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnZTWM2OD1{MT6zOlAzKM7:TR?=M1L4cXNCVkeHUh?=
GR-STMmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXYdWNKSzVyPUKxMlQyPyEQvF2=NG\VSGdUSU6JRWK=
CHP-126M1nWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTJzLk[xPFEh|ryPM2ToUHNCVkeHUh?=
EHEBNVzB[pBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIeyZVZKSzVyPUKxMlY4OzFizszNNGrOR3hUSU6JRWK=
CPC-NMl7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHQbmpKSzVyPUK0MlAzODFizszNMY\TRW5ITVJ?
NB1NXXsPJNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTJ2Lk[5N|kh|ryPMUfTRW5ITVJ?
LS-123M2rxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWS2TGh3UUN3ME2yOE46ODF{IN88US=>NXSwWZUyW0GQR1XS
ST486MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2j1NWlEPTB;MkWuNVEyOyEQvF2=MYnTRW5ITVJ?
NCI-H1963M1;lPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3oNIxKSzVyPUK2MlA3OjNizszNMUPTRW5ITVJ?
U-87-MGNUPCfmx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7uV5JKSzVyPUK2Mlc3PDRizszNMWDTRW5ITVJ?
COR-L279MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnWRYptUUN3ME2yOk44QTJ{IN88US=>NVOxUW42W0GQR1XS
LU-165MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjxRmJKSzVyPUK4MlA5PjFizszNNGPnc5dUSU6JRWK=
COLO-800M3\STGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmW4TWM2OD1{OD6yPVU3KM7:TR?=M3Txe3NCVkeHUh?=
ETK-1NHLs[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTJ6LkO0OFYh|ryPMWPTRW5ITVJ?
LNCaP-Clone-FGCM{Pic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjUVGtZUUN3ME2yPU46OjhzIN88US=>M2ju[3NCVkeHUh?=
SIG-M5NEK5RmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDDbppKSzVyPUOwMlc6PTJizszNNVrKT41{W0GQR1XS
NB6NFjvN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTNyLkm1NFMh|ryPM2DwZ3NCVkeHUh?=
NCI-H2107NUXESZF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LFfGlEPTB;M{GuNlM{QCEQvF2=M1i4fXNCVkeHUh?=
SNU-C1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnGfmlkUUN3ME2zNU4{OTJ4IN88US=>NVHKb4hbW0GQR1XS
JARM2HZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHQN3k4UUN3ME2zNU4{Pzl7IN88US=>MVfTRW5ITVJ?
L-363NXfOZZlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTN{LkKxOFQh|ryPMV7TRW5ITVJ?
EW-24MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3SZmoxUUN3ME2zNk4{PDd2IN88US=>MoDxV2FPT0WU
NB69NGTVTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTN|Lk[0OVQh|ryPNYDTPFRwW0GQR1XS
EW-13MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLUTWM2OD1|Mz64PVY6KM7:TR?=MVvTRW5ITVJ?
Ramos-2G6-4C10NYfrfFdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rjV2lEPTB;M{SuNlk6OyEQvF2=MlP2V2FPT0WU
TE-11NHH2OpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1i1[GlEPTB;M{SuOFgzOiEQvF2=NIrqVVFUSU6JRWK=
L-428NVzwZ5VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTN2Lke1N|Yh|ryPMnzkV2FPT0WU
KP-N-YNM3PkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTN2LkmwOVch|ryPNITsfW5USU6JRWK=
CGTH-W-1M{nqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoraTWM2OD1|Nj65NFQ5KM7:TR?=NYryeIdkW0GQR1XS
K-562MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7zPYZKSzVyPUO3MlA5PjRizszNNHHaNWRUSU6JRWK=
NCI-H1299MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\HTmlEPTB;M{iuNVYxOyEQvF2=NHrjfHBUSU6JRWK=
RCC10RGBM{HRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\UdGlEPTB;M{iuNlA5OyEQvF2=NVrTdYtoW0GQR1XS
NCI-SNU-16MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlP5TWM2OD1|OD61OlU{KM7:TR?=M125WXNCVkeHUh?=
LC-2-adNULYSoRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2T5NWlEPTB;M{muOFM{PyEQvF2=MXvTRW5ITVJ?
MHH-PREB-1NUDoXVBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfrfmk4UUN3ME2zPU44Ozh6IN88US=>NXnITmNzW0GQR1XS
NCI-H64MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmH2TWM2OD12MD6wPVQ5KM7:TR?=M{DOcXNCVkeHUh?=
LB996-RCCMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTGZlFDUUN3ME20NE45PzF4IN88US=>M2TPc3NCVkeHUh?=
DELNGH5b2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTDfoJKSzVyPUSxMlQ1ODVizszNNVHYNmlLW0GQR1XS
MLMANIPJTXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rhV2lEPTB;NEGuO|U6PSEQvF2=NFXTUINUSU6JRWK=
SBC-1M3TkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTR{LkG4NFYh|ryPM3nWSXNCVkeHUh?=
MPP-89Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;wdGlEPTB;NEKuOVg4PSEQvF2=M4rKTnNCVkeHUh?=
MV-4-11M2DL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\NPWlEPTB;NEKuPVA3PyEQvF2=M1;rXnNCVkeHUh?=
EoL-1-MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M37Zb2lEPTB;NESuNVU3QCEQvF2=NGi1[JRUSU6JRWK=
CW-2NWjmSWJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfXNnJKSzVyPUS0Mlg{PDJizszNM4nTbXNCVkeHUh?=
HTMkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PDNWlEPTB;NEWuO|AxPyEQvF2=M3LGbXNCVkeHUh?=
SW954Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvuSoM{UUN3ME20O{41OTJ6IN88US=>M3vSNHNCVkeHUh?=
A3-KAWNHXrZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkO1TWM2OD12OT64NFYyKM7:TR?=NVSxXlNlW0GQR1XS
TC-YIKM4rPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvTTnNKSzVyPUWwMlA{PjNizszNNX;yTZJCW0GQR1XS
SW962MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1noUGlEPTB;NUSuPFM2PyEQvF2=NFPVSGpUSU6JRWK=
KP-N-RT-BM-1M3\zWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlf5TWM2OD13Nj62OlM5KM7:TR?=M1vlR3NCVkeHUh?=
NCI-H1395NFjwXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4ftWWlEPTB;NUiuPFE4OiEQvF2=MWLTRW5ITVJ?
RPMI-8402M3PzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4Gwe2lEPTB;NUiuPVUzPiEQvF2=NH7ndHJUSU6JRWK=
SCHNHizbmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;FSmlEPTB;NkCuPVY{QCEQvF2=MoHhV2FPT0WU
NCI-H2196M1TVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fyOWlEPTB;NkGuNlMyKM7:TR?=MnLVV2FPT0WU
LOXIMVIMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;hTWM2OD14MT64NlY3KM7:TR?=Mlm2V2FPT0WU
TGBC24TKBMlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXwTYhKSzVyPU[yMlE1QTFizszNMWXTRW5ITVJ?
SK-MEL-2M4nCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnHVY9zUUN3ME22N{46QDl{IN88US=>NVnENldxW0GQR1XS
U-698-MNV75VZg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHUTWM2OD14OD61Olg4KM7:TR?=NUC0cpRPW0GQR1XS
NCI-H1522NVTlbHNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\ZSZNOUUN3ME22PU4xODR5IN88US=>NWTKcFl6W0GQR1XS
UACC-812NVrN[HVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnPSmhxUUN3ME22PU42OjB7IN88US=>MkTpV2FPT0WU
MHH-CALL-2M33WUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn:1TWM2OD15MD6wOkDPxE1?M3\nb3NCVkeHUh?=
NB5NV60U444T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLPTWM2OD15MD6zOFY5KM7:TR?=MUHTRW5ITVJ?
KARPAS-299MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;tTWM2OD15MD60OFQ4KM7:TR?=NX3iSYRSW0GQR1XS
NCI-H1694M3fN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PYVGlEPTB;N{GuNFMzKM7:TR?=MlHIV2FPT0WU
NCI-H82MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF[ybGJKSzVyPUexMlk2ODdizszNMoOzV2FPT0WU
SCC-15NV\hT3M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYntN45EUUN3ME23Nk4{PCEQvF2=NW\6bml2W0GQR1XS
NCI-H1436M{XaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTd{Lke0OVYh|ryPM1znTHNCVkeHUh?=
ATN-1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFniXFdKSzVyPUe0MlUxPSEQvF2=NIrxWVdUSU6JRWK=
RPMI-8866NVTUZpdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYi1UVhFUUN3ME23OE44PTB7IN88US=>NXOzTXl5W0GQR1XS
HCC1599Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTd2Lki3N|Ih|ryPM4[xR3NCVkeHUh?=
NCI-H1155NYHMZWtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTMVmlMUUN3ME23OE46OzZ5IN88US=>M3j2PXNCVkeHUh?=
DOHH-2MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPke|lKSzVyPUe0Mlk2OTRizszNM4P5dHNCVkeHUh?=
SK-NEP-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGS4V4VKSzVyPUe1MlA4PTRizszNMV\TRW5ITVJ?
HCC1187NIXI[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVSyUo5lUUN3ME23O{43OTJ{IN88US=>M{\XXHNCVkeHUh?=
NCI-H322MM3HhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXpZmNmUUN3ME23PE4{PzB7IN88US=>M4m4e3NCVkeHUh?=
NCI-H526MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TDU2lEPTB;N{iuOVg4PyEQvF2=MmD3V2FPT0WU
NCI-H2171NWfRT4NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1flcmlEPTB;N{muOFE{PiEQvF2=MmGyV2FPT0WU
COLO-668NELq[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofrTWM2OD16MT61PFg1KM7:TR?=NEHqc2VUSU6JRWK=
RS4-11MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTh{LkK1NFUh|ryPNX7aO2U2W0GQR1XS
NCI-H716NF\RS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTh{LkmwO|Uh|ryPMl3VV2FPT0WU
LU-134-ANWrKV3dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjNN3hKSzVyPUizMlE{PTFizszNMUDTRW5ITVJ?
RPMI-8226NH;LTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fjb2lEPTB;OESuNlExPyEQvF2=M2rQV3NCVkeHUh?=
KY821M2D0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PmbWlEPTB;OUGuOlU2OSEQvF2=MWPTRW5ITVJ?
ECC4NUXMeW96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjjeoJKSzVyPUmzMlgzPjlizszNMlzNV2FPT0WU
EW-3MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mly0TWM2OD17ND65NFgyKM7:TR?=Mn2wV2FPT0WU
NB7NEDDN|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTl3Lke3PFYh|ryPNHnkT3FUSU6JRWK=
NCI-H720MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlX0TWM2OD17OD60NFYyKM7:TR?=NIjheHRUSU6JRWK=
NCI-H446NVjvZph{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LJbmlEPTB;OUmuO|U5QCEQvF2=MXvTRW5ITVJ?
NCI-H889MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTFyND6yOFIh|ryPMUXTRW5ITVJ?
EW-22NIPZO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTFyNj6xPUDPxE1?MoHYV2FPT0WU
BV-173M4\U[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTFyOD63Nlgh|ryPM1vvbnNCVkeHUh?=
WSU-NHLM3TvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLsfXpWUUN3ME2xNFkvPjdzIN88US=>NUjHXGNYW0GQR1XS
MN-60NG\Ue|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPnNmNMUUN3ME2xNFkvPjlizszNNXPWVZdNW0GQR1XS
DG-75NFPGUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPMWXhKSzVyPUGxN{4{PTJizszNNHf0R|dUSU6JRWK=
DMS-79MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrMUXl7UUN3ME2xNVcvOzh{IN88US=>M4nkNXNCVkeHUh?=
SK-MEL-1MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWC2WFBPUUN3ME2xNVgvODB7IN88US=>NIfwXopUSU6JRWK=
DMS-153NUDwd4RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHORph2UUN3ME2xNlEvPzR3IN88US=>M1qwZXNCVkeHUh?=
NCI-H510ANHe5TotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfVTWM2OD1zMkeuN|Ih|ryPMnvIV2FPT0WU
BE-13MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTF|ND6wOFQh|ryPMYrTRW5ITVJ?
KP-N-YSMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkK2TWM2OD1zM{muO|M3KM7:TR?=MkG0V2FPT0WU
SUP-T1MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTF2Mz63NFgh|ryPNV6welBDW0GQR1XS
EW-12M33ifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfzcnp2UUN3ME2xOFQvPjl7IN88US=>M2r0SnNCVkeHUh?=
NB14Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PnUmlEPTB;MUS3MlA5OiEQvF2=MYDTRW5ITVJ?
MDA-MB-134-VIMnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTF2OD6yOlgh|ryPNH;vXZhUSU6JRWK=
NCI-H1770MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPqTWM2OD1zNU[uNlc6KM7:TR?=MV\TRW5ITVJ?
TURNGnVfohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTF4Nz64O{DPxE1?M1\wWnNCVkeHUh?=
NCI-H1417M17t[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWf5[3FCUUN3ME2xPFAvOzNzIN88US=>MmDCV2FPT0WU
IMR-5NXu4bHhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\wO2lEPTB;MUixMlU4OSEQvF2=M1Wy[nNCVkeHUh?=
NCI-H226NHvt[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mon6TWM2OD1zOEiuPFY3KM7:TR?=NUDHelRWW0GQR1XS
NCI-H187Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTXOJVKSzVyPUG5NE4xPjRizszNNGjCU2tUSU6JRWK=
SF539NGO3WmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPyU3FKSzVyPUG5Nk44OjhizszNM4q2bHNCVkeHUh?=
TALL-1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkC1TWM2OD1zOUiuN|A1KM7:TR?=NUTGZ|RzW0GQR1XS
TE-441-TMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXVXZRKSzVyPUG5PU44OzlizszNNXfwUop1W0GQR1XS
REHMoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWH2dZhEUUN3ME2yN|YvPjJ4IN88US=>MmrvV2FPT0WU
MS-1NHHMWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTJ|OT6xNlEh|ryPM33NN3NCVkeHUh?=
THP-1NWnrWXpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTJ4ND63N|gh|ryPMV7TRW5ITVJ?
NCI-H1838M4PaXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTJ5MT60OVYh|ryPNIHRPGFUSU6JRWK=
P30-OHKNHviN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHHU4hDUUN3ME2yPFMvQDR5IN88US=>NHewRmFUSU6JRWK=
C8166MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzqTWM2OD1|NEWuN|M5KM7:TR?=NVTNNYhvW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Measurement of inhibitory activities of MG-132 against 20S proteasome The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.

Cell Assay:

[3]

Cell lines KIM-2, HC11, and ES
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 24, and 48 hours
Method

Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.

Animal Study:

[7]

Animal Models Male mdx (C57BL/10ScSn DMD mdx) mice
Formulation Dissolved in DMSO, and diluted in PBS
Dosages ~10 μg/kg/day
Administration Injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tsubuki S, et al. J Biochem, 1996, 119(3), 572-576.

[2] Fiedler MA, et al. Am J Respir Cell Mol Biol, 1998, 19(2), 259-268.

view more

Chemical Information

Download MG-132 SDF
Molecular Weight (MW) 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 95 mg/mL (199.73 mM)
Ethanol 95 mg/mL (199.73 mM)
Water <1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate

Customer Product Validation (9)


Click to enlarge
Rating
Source Nat Cell Biol 2015 17(1), 95-103. MG-132 purchased from Selleck
Method Immunoprecipitation
Cell Lines MDA-MB-231 cells
Concentrations 10 uM
Incubation Time 6 h
Results SIAH2 destabilizes LATS2 through proteasome. SIAH2-mediated LATS2 degradation was inhibited by proteasomal inhibitor MG132, but not by lysosomal inhibitor BA-1. The half-life of LATS2 was shortened by SIAH2.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck
Method Western blot
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results As RMND5A downregulation resulted in a rapid decrease of protein Exportin-5, this effect was partially abolished by the proteasome inhibitor MG132, indicating that RMND5A protect Exportin-5 protein against proteasome degradation.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck
Method Immunocytochemistry
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results It was surprised to observe that Exportin-5 retention in nucleus when its protein levels were downregulated by RMND5A siRNA or miR-138. The proteasome inhibitor MG132 could recover not only Exportin-5 protein levels but also its normal subcellular localization.

Click to enlarge
Rating
Source EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck
Method Western Blot
Cell Lines MEF cells
Concentrations 30 uM
Incubation Time 6 h
Results Treatment of MEF with proteasome inhibitor MG132 resulted in similar increase of steady state levels of intracellular ATZ in both GFP- and TFEB- transfected Cells.

Click to enlarge
Rating
Source Cell Rep 2015 11(9), 1458-73. MG-132 purchased from Selleck
Method Western Blot
Cell Lines A375, Lu1205 cells
Concentrations 5 uM
Incubation Time 10 h
Results MG132 treatment increased JAK1 steady-state levels, masking the effect of RNF125 depletion and partially blocking deregulated JAK1 expression by ectopically expressed RNF125.

Click to enlarge
Rating
Source Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck
Method Immunoblot analysis
Cell Lines Arabidopsis thaliana
Concentrations 100 uM
Incubation Time 12 h
Results These rates of loss were markedly slower in the lrb1-1 lrb2-1 background. Importantly, phyB breakdown was also substantially attenuated upon exposing wild-type seedlings to the proteasome inhibitor MG132, thus implicating the 26S proteasome in particular. MG132 treatment also slightly stabilized phyB levels in lrb1-1 lrb2-1 seedlings, implying that other factors besides LRB1 and LRB2 might also direct phyB breakdown.

Click to enlarge
Rating
Source Toxicol Appl Pharmacol 2015 286(2), 135-41. MG-132 purchased from Selleck
Method Immunofluorescence
Cell Lines γ-H2AX-stained cells
Concentrations 100 uM
Incubation Time 3 h
Results G2 cell cycle arrest usually reflects the formation of genomic damage in the preceding S-phase, which activates checkpoint response upon the entry of cells into G2 phase. Furthermore, MG132-treated cells also had larger amounts of γ-H2AX, as evidenced by the increased staining in individual nuclei .

Click to enlarge
Rating
Source FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck
Method Western Blot
Cell Lines Hela cells
Concentrations
Incubation Time 12 h
Results When GSK-3 (Ser9) degradation was blocked by proteasome inhibitor (MG132), the increased amount of phosphorylated GSK-3 (Ser9) in responding to NOK was more clearly observed in the HeLa-NOK-HA cells (Fig. C).

Click to enlarge
Rating
Source 2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck
Method Western blot
Cell Lines NIH3T3 cells
Concentrations 25 μM
Incubation Time 1-4 h
Results By adding MG132, a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • Bortezomib (PS-341)

    Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Recently Viewed Items

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us